Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients

Transplantation

Volumn 88, Issue 7, 2009, Pages 891-896

  Klem, Patrick ^a   Cooper, James E ^b   Weiss, Andrew S ^b   Gralla, Jane ^c   Owen, Phillip ^a   Chan, Laurence ^b   Wiseman, Alexander C ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Children's Hospital Colorado   (United States)

Author keywords

Acute rejection; ATG; Induction; Kidney transplantation; Thymoglobulin

Indexed keywords

CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

AFRICAN AMERICAN; ARTICLE; BK VIRUS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; FEMALE; GRAFT DYSFUNCTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAOPERATIVE PERIOD; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LENGTH OF STAY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; PYELONEPHRITIS; RETRANSPLANTATION; RETROSPECTIVE STUDY; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANIMALS; ANTILYMPHOCYTE SERUM; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-D ANTIGENS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; PATIENT DISCHARGE; PATIENT SELECTION; RABBITS; REOPERATION; RETROSPECTIVE STUDIES; RISK; SURVIVAL RATE; SURVIVORS; TIME FACTORS;

EID: 73249138739     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b6f38c     Document Type: Article

References (27)

1. Shapiro R, Young JB, Milford EL, et al. Immunosuppression: Evolution in practice and trends, 1993-2003. Am J Transplant 2005; 5: 874-886.
2. Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967-1977. (Pubitemid 44708016)
3. Hardinger KL, Rhee, S, Buchanan P, et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation 2008; 86: 947-952.
4. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6: 1111-1131.
5. Randhawa P, Brennan DC. BK virus infection in transplant recipients: An overview and update. Am J Transplant 2006; 6: 2000-2005. (Pubitemid 44199534)
6. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 2823-2831.
7. Opelz G, Naujokat C, Daniel V, et al. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006; 81: 1227-1233. (Pubitemid 43804539)
8. Smith JM, Dharnidharka VR, Talley L, et al. BK virus nephropathy in pediatric renal transplant recipients: An analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol 2007; 2: 1037-1042.
9. Thymoglobulin [package insert]. Genzyme Corporation, Cambridge, MA. 2008.
10. Buchler M, Hurault de Ligny B, Madec C, et al; French Thymoglobuline Pharmacovigilance Study Group. Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: A 1-yr follow-up of safety and efficacy. Clin Transplant 2003; 17: 539-545.
11. Djamali A, Turc-Baron C, Portales P, et al. Low dose antithymocyte globulins in renal transplantation: Daily versus intermittent administration based on T-cell monitoring. Transplantation 2000; 69: 799-805. (Pubitemid 30174100)
12. Agha IA, Rueda J, Alvarez A, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 2002; 73: 473-475. (Pubitemid 34174301)
13. Hardinger KL, Schnitzler MA, Koch MJ, et al. Thymoglobulin induction is safe and effective in live-donor renal transplantation: A single center experience. Transplantation 2006; 81: 1285-1289.
14. Stevens RB, Mercer DF, Grant WJ, et al. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: An interim report. Transplantation 2008; 85: 1391-1399.
15. Wong W, Agrawal N, Pascual M, et al. Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int 2006; 19: 629-635.
16. Goggins, WC, Pascual MA, Powelson JA, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003; 76: 798-802.
17. + lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation 2002; 73: 1514-1518.
18. Gurk-Turner C, Airee R, Philosophe B, et al. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. Transplantation 2008; 85: 1425-1430.
19. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation, versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564-577.
20. Gralla J, Wiseman A. Tacrolimus/sirolimus versus tacrolimus/ mycophenolate in kidney transplantation: Improved 3-year graft and patient survival in recent era. Transplantation 2009; 87: 1712.
21. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461-470.
22. Ninova D, Covarrubias M, Rea DJ, et al. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: Differential intragraft expression of transforming growth factor-beta 1 and alpha-smooth muscle actin. Transplantation 2004; 78: 338-344. (Pubitemid 39095398)
23. Shihab FS, Bennett WM, Yi H, et al. Sirolimus increases transforming growth factor-betal expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004; 65: 1262-1271. (Pubitemid 38406964)
24. Augustine JJ, Chang PC, Knauss TC, et al. Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients. Transplantation 2006; 81: 1004-1009.
25. Pallet N, Thervet E, Alberti C, et al. Kidney transplantation in black recipients: Are African Europeans different from African Americans? Am J Transplant 2005; 5: 2682-2687. (Pubitemid 43920061)
26. Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - A prospective randomized study. Transplantation 1999; 68: 1865-1874. (Pubitemid 30027339)
27. US Organ Procurement and Transplantation Network & Scientific Registry of Transplant Recipient. OPTN/SRTR Annual Report, 2007, Table 5.10a. Available at: http://www.ustransplant.org/annual-reports/current/510a-can-last- cur-pra-ki.htm. Accessed March 1, 2009.